When the Food and Drug Administration approved Gleevec to treat a form of leukemia in 2001, it ushered in a new era in cancer care.

Donnalee Lozeau is the director of a new statewide program that will distribute roughly $200 million in federal funding this year toward rural healthcare needs in New Hampshire. Over five years, the state expects to receive a total of $1 billion dollars.

New Hampshire's Therapeutic Cannabis Program saw a 15% increase in patients last year.

Attorney General John Formella announces that New Hampshire would get about $30 million from the $7.4 billion opioid settlement reached with Purdue Pharma and its owners, the Sackler family. The money will go toward drug treatment and recovery.

Abortion advocates had alternative options but say mifepristone remains safe and effective.

As part of the merger, Beth Israel Lahey Health had pledged to maintain and expand access to clinical services at Exeter Hospital, including a planned $375 million capital investment over 10 years.

A federal appeals court has restricted access to one of the most common means of abortion in the U.S. by blocking the mailing of mifepristone.

U.S. Sen. Maggie Hassan’s letter cites “troubling allegations” against a methadone clinic's business practices and care.

Plaintiffs alleged the state failed to properly administer the Choices for Independence program, leading some recipients to be at risk of institutionalization.

Acting Attorney General Todd Blanche said he is immediately moving medical marijuana from Schedule I to Schedule III, which includes drugs like ketamine, Tylenol with codeine and anabolic steroids.